AtheroGenics, Inc.{AGIX}-nasdaq Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Clarksterh who wrote (302)	9/7/2007 1:25:21 PM
From: Clarksterh	of 332

Lots of new results in the presentation just made. But probably the most significant is the excess rate of CHF in the treated group (p=0.08 by my calc) and the excess rate of Atrial Fib (p=0.0005 by my calc). The first was talked about in earlier CC, but without hard numbers that I can remember. But the second item, Atrial Fib, was not talked about at all. Oddly, despite the significantly higher incidence of Atrial Fib (a leading cause of stroke) the stroke rate reduction was the biggest benefit of 1067 from a hazard ratio perspective. Perhaps because of the anti-clotting aspects of 1067 (almost twice as many bleeding SAEs)? All in all I'd say that 1067 is dead from a heart disease perspective with the effect on CHF and Atrial Fib and no effect on cardiac mortality (all the efficacy was MI and stroke) - so this probably explains it being dropped by AZN. No comment yet on the diabetes aspects discussed in the presentation. FWIW - Again I have to applaud Atherogenics for being so open with bad news. A lot of companies clamp down on bad news.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next